Immuron (ASX:IMC)
We spoke to Immuron CEO Steve Lydeamore about the clinical work it is doing with IMM-124e and IMM-529, its involvement with the Uniformed Services University and the Naval Medical Research Command, and the commercial opportunity for Travelan now that people are travelling again.
Check out the in-depth research on Immuron by Pitt Street Research!
Check our ASX buy/sell tips
